Study: Medical Cannabis Making Inroads in Prescription Drug Market

Medical cannabis has likely made a serious dent in the prescription drug industry – to the tune of $165 million in market share in 2013, according to a new study published in the journal Health Affairs.

The study’s authors examined prescription information filled by Medicare Part D enrollees between 2010-2013. They looked specifically at ailments that could have been alternatively treated by cannabis, such as depression, anxiety, nausea, pain and glaucoma, Medical News Today reported.

As of 2013, 17 U.S. states and Washington, D.C., had legalized medical marijuana.

The analysis found that during those three years, the use of prescription medication took a nosedive. Daily doses of prescription drugs for pain shrunk by 1,826, for example, while doses for depression went down by 265.

The researchers estimated that the reduced reliance on prescription drugs equated to a savings of $165 million. The findings indicate the money is instead going toward medical cannabis as an alternative treatment.

The same study also estimated that if the entire United States had legalized MMJ in 2013, the populace would have saved $468 million that year on prescription drugs, much of which probably would have gone to cannabis sales.

Daily News | Briefs | Dispensary/Retail Store Business News | Sales, Funding & Banking News


  1. Clif July 12, 2016
    • Mark July 12, 2016
  2. Michael Davis July 12, 2016
  3. Saul Immanuel July 12, 2016

Leave a Reply

Your email address will not be published. Required fields are marked *

Please note: Comments are moderated by our editors who do their best to approve comments ASAP. As Marijuana Business Daily is focused on business, we approve comments that are specifically relevant to industry professionals. General opinions and questions about cannabis may not be posted.